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                                             AIM 
To evaluate the prognostic value of early post operative GH measurements with regards 
to remission of the disease after surgery for GH secreting pituitary adenomas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 9  
INTRODUCTION 
 
Anatomy and physiology 
 
The pituitary (Figure 1) is a bean-shaped gland located at the base of the brain in the 
midline. It measures 0.6 cm x 0.9 cm x 1.3 cm and an average gland weighs 0.6 grams. 
The gland lies within the bony sella turcica. The pituitary is composed of two 
anatomically and functionally distinct parts: the neurohypophysis and the 
adenohypophysis. 
 
The neurohypophysis is composed of the infundibulum, the pituitary stalk, and the pars 
nervosa of the pituitary. The cell types of the neurohypophysis include pituicytes, which 
are modified glial cells, and the axonal processes of neurons whose cell bodies are 
located in the hypothalamus. The neurohypophysis stores and releases the hypothalamic 
hormones oxytocin and vasopressin. 
 
The adenohypophysis is of ectodermal origin, embryologically derived from Rathke's 
pouch. It has three regions, the pars distalis or anterior lobe, the pars intermedia or 
intermediate lobe and the pars tuberalis, an extension of epithelium that wraps around the 
infundibulum of the pituitary stalk. 
 
The adenohypophysis is composed of acini that contain the specialized cell types, all of 
which have their own unique hormonal function and characteristics. The molecular  
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Figure1. Normal anatomy of the human hypothalamic-pituitary unit in sagittal (A) and 
coronal planes (B). 
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factors that determine hormone production are transcription factors that target specific 
hormone genes. Somatotrophs, lactotrophs, mammosomatotrophs, and thyrotrophs all 
derive from growth hormone (GH)-producing precursors. 
 
GH-producing somatotrophs are located in the lateral wings of the anterior pituitary and 
account for approximately 50% of the cell population. By light microscopy they are 
strongly acidophilic cells with centrally located nuclei and diffuse cytoplasmic positivity 
for GH. Mammosomatroph cells expressing both prolactin and GH arise from the 
acidophilic stem cell and immunostain mainly for prolactin. 
 
The pituitary receives its vascular supply from the superior, middle, and inferior 
hypophyseal arteries, all of which originate from the internal carotid arteries. 
 
 
Growth Hormone and Insulin-like Growth Factor-1 
The GH molecule, a single-chain polypeptide hormone consisting of 191 amino acids, is 
synthesized, stored, and secreted by somatotroph cells and the human GH genome locus 
is located on the long arm of human chromosome 17q22-24. GH is under regulation of 
GHRH (growth hormone releasing hormone) and SRIF (somatotropin release inhibiting 
factor) also known as Somatostatin, from the hypothalamus.  The half-life of GH is short, 
25 – 30 minutes, long enough to enable its uptake by the liver where it induces the 
production of insulin-like growth factor (IGF-1) known in older literature as 
somatomedin-C.  GH does have direct effects on receptors on target cells such as 
 12  
adipocytes where it induces the break down of triglycerides and suppresses the reuptake 
and accumulation of lipids.   GH secretion is further regulated by its target growth factor, 
IGF-I, which participates in a hypothalamic pituitary peripheral regulatory feedback 
system. GH stimulates IGF-I, which exerts a negative-feedback effect on the 
hypothalamus and pituitary. IGF-I stimulates hypothalamic SRIF release and inhibits 
pituitary GH gene transcription and secretion. 
IGF-1 is a trophic factor and mediates most effects of GH, through binding with IGF 
receptors that exist in almost every cell in the human body, particularly in muscle, 
cartilage, bone, liver, kidney, nerves, skin and lungs.    
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Acromegaly 
 
In 1886, Pierre Marie (1) published the first clinical description of disordered somatic 
growth and proportion and proposed the name acromegaly. Cushing, Davidoff, and 
Bailey (2, 3) documented the clinicopathologic features of acromegaly and demonstrated 
clinical remission of soft tissue signs after adenoma resection. The prevalence of 
acromegaly is estimated to range from 38 to 69 cases/million, and the annual incidence of 
new patients is 3 or 4 per million (4). Acromegaly is caused by pituitary tumors secreting 
GH or very rarely by extrapituitary disorders. GH secreting pituitary adenomas constitute 
10% of all pituitary tumors (5).  Regardless of the etiology, the disease is characterized 
by elevated levels of GH and IGF-I, with resultant signs and symptoms of 
hypersomatotrophism.  
Feedback loops involve both GH and IGF-1 that have inhibitory autocrine effects on the 
pituitary and hypothalamus.   In acromegaly, GH hypersecretion from pituitary adenomas 
and rarely from ectopic sources in some malignant tumors continues unchecked since 
these inhibitory feedback loops are non-functional.   
 
More than 95% of patients with acromegaly harbor a GH-secreting pituitary adenoma. 
Extrapituitary acromegaly accounts for the remaining 5% (6). Pure GH-cell adenomas 
contain either densely or sparsely staining cytoplasmic GH granules, and these two 
variants are either slow growing (densely granulated) or rapidly growing (sparsely 
granulated)(7). The former arise insidiously and manifest during or after middle age; the 
latter arise in younger subjects with more florid disease. Mixed GH-cell and PRL-cell 
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adenomas are composed of distinct somatotrophs expressing GH and lactotrophs 
expressing PRL. Monomorphous acidophil stem cell adenomas arise from the common 
GH and PRL stem cell and also often contain giant mitochondria and misplaced GH 
granule exocytosis. They grow rapidly, are invasive, and manifest with predominant 
features of hyperprolactinemia (8). 
 
  
Manifestations of acromegaly are caused by either central pressure effects of the pituitary 
mass or peripheral actions of excess GH and IGF-I. Central features of the expanding 
pituitary mass are common to all pituitary masses. In acromegaly, headache is often 
severe and debilitating. Local signs are especially important presenting features because a 
higher preponderance of macroadenomas (>65%) is encountered in acromegaly, as 
compared to mostly microadenomas for PRL-secreting tumors (9). The clinical features 
are summarized in Table 1.  
 
Effects of hypersomatotrophism on acral and soft tissue growth, and metabolic function, 
occur insidiously over several years. The slow onset and elusive symptomatology often 
results in delayed diagnosis ranging from 6.6 to 10.2 years, with a mean delay of almost 9 
years (10).  However in a recent study, Natchigall et al (30) showed a much shorter mean 
time to diagnosis (2.5 years) than previously reported in the literature and the diagnosis 
was suspected by the primary care physician in 44% of the cases.  
 
 15  
 
                                                 Table -1 
                  CLINICAL FEATURES OF ACROMEGALY  
LOCAL TUMOR EFFECTS 
    Cranial nerve palsy 
    Headache 
    Pituitary enlargement 
    Visual field defects 
 
SOMATIC EFFECTS 
Acral Enlargement 
Thickness of hand and feet soft tissue 
Cardiovascular 
    Asymmetric septal hypertrophy
    Cardiomyopathy 
    Congestive heart failure 
    Hypertension 
    Left-ventricular hypertrophy 
 
Colon 
Polyps 
Musculoskeletal 
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    Acroparesthesia 
    Arthralgias and arthritis 
    Carpal tunnel syndrome 
    Gigantism 
    Hypertrophy of frontal bones
    Jaw malocclusion 
    Prognathism 
    Proximal myopathy 
 
Pulmonary 
    Narcolepsy 
    Sleep apnea—central and obstructive
    Sleep disturbances 
 
Skin 
    Hyperhidrosis 
    Oiliness 
    Skin tags 
 
VISCEROMEGALY 
    Kidney 
    Liver 
    Prostate 
 17  
    Salivary gland 
    Spleen 
    Thyroid 
    Tongue 
 
ENDOCRINE AND METABOLIC EFFECTS 
Carbohydrate 
    Diabetes mellitus 
    Impaired glucose tolerance 
    Insulin resistance and hyperinsulinemia
 
Electrolytes 
    Increased aldosterone 
    Low renin 
 
Lipids 
Hypertriglyceridemia 
Minerals 
    Hypercalciuria, increased 1,25(OH)2D3
    Urinary hydroxproline 
 
Multiple endocrine neoplasia type 1 
    Hyperparathyroidism 
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    Pancreatic islet cell tumors
 
Reproduction 
    Decreased libido, impotence, low sex hormone–binding globulin 
    Galactorrhea 
    Menstrual abnormalities 
 
Thyroid 
    Goiter 
    Low thyroxine-binding globulin
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Patients might seek care for dental, orthopedic, rheumatologic, or cardiac disorders. Only 
13% of 256 patients whose acromegaly was diagnosed during a 20-year period presented 
with primary symptoms of altered facial appearance or enlarged extremities (11).   In a 
review of several hundred patients presenting with acromegaly worldwide, 98% had acral 
enlargement, and hyperhidrosis was prominent in 70 % (12).  Nachtigall et al (30) did a 
retrospective analysis of 100 cases of acromegaly and found that the presenting 
symptoms in decreasing order were acral changes (24%), followed by headaches (20%), 
amenorrhea (6% of total, 11% of women), dental changes (4%), carpal tunnel syndrome 
(4%), visual deficits (3%), sexual dysfunction (3%), arthralgias (2%), galactorrhea (2%), 
chest pain (2%), uncontrolled hypertension (2%), diabetes (1%), dizziness (1%), 
gynecomastia (1% of total, 2% of men), weakness (1%), and weight gain (1%). 
Characteristic features include large fleshy lips and nose, spade-like hands, frontal skull 
bossing, and cranial ridges. Enlarged tongue, bones, salivary glands, thyroid, heart, liver, 
and spleen are the effects of generalized visceromegaly. Clinically apparent 
hepatosplenomegaly, however, is rare. Increase in shoe, ring, or hat size is commonly 
reported. Progressive acral changes can lead to facial coarsening and skeletal 
disfigurement, especially if excess GH secretion begins prior to epiphyseal closure. These 
include mandibular overgrowth with prognathism, maxillary widening, teeth separation, 
jaw malocclusion, overbite, large nose, and coarse, oily skin with large pores. Sonorous 
voice deepening occurs in association with laryngeal hypertrophy and enlarged paranasal 
sinuses. Arthropathy occurs in 70% of the patients (13). Hyperhidrosis and malodorous 
skin in seen in upto 70% of patients (14). Acromegaly is associated with increased 
morbidity and mortality, mainly secondary to cardiovascular disease.  
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LITERATURE REVIEW: 
 
Clinical, biochemical and radiological diagnosis 
 
The diagnosis of acromegaly is usually made clinically on the history and typical external 
appearance. GH and IGF-1 levels are elevated in acromegaly (15). In contrast to GH 
levels, plasma levels of IGF-I are more stable, and an elevated IGF-I level in a patient 
with appropriate clinical suspicion is almost always indicative of acromegaly(16). For 
accurate control comparison, the IGF-I level must be age and gender matched.  
 
The various methods for GH assay include radioassays and immunoassays. The previous 
polyclonal radioassay techniques had a sensitivity of 0.5 ng/ml whereas the current 
immunoassays have sensitivity as low as 0.01 ng/ml. Freda at al (55) showed that 
immunoradiometric assays are superior to radioimmunoassays in distinguishing between 
patients with active disease and healthy subjects. Arafat et al (18) compared three 
different immunoassays [Immulite (Diagnostic Products Corp., Los Angeles, CA), 
Nichols (Nichols Institute Diagnostika GmbH, Bad Vilbel, Germany), and Diagnostic 
Systems Laboratories (Sinsheim, Germany)] tested on 46 acromegaly patients and 213 
healthy subjects. They concluded from the study that nadir GH levels are assay, gender, 
age, and BMI specific, indicating the need of individual cutoff limits for each assay. 
Using cutoff limits of 1 ug/liter (Immulite) and 0.5ug/liter (Nichols) identified 95% of 
patients with active disease and 78–80% of patients in remission. 
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When growth hormone is measured in healthy persons with the use of standard assays, 
the level is usually undetectable (<0.2 µg per liter throughout most of the day), but  
there are approximately 10 intermittent pulses of growth hormone per 24 hours, most 
often at night, when the level can be as high as 30 µg per liter(19). In normal individuals 
GH suppression occurs after a glucose load. Improved assays with increased sensitivity 
have suggested that serum GH levels should normally be suppressed following an oral 
glucose load to less than 0.057 ng/mL in men and less than 0.71 ng/mL in women (20). 
Freda et al (21) showed that in normal subjects the nadir GH level after a glucose load is 
less than 0.14 ng/ml. The exact mechanism is not known but it is considered to be due to 
somatostatin release in response to glucose load. In acromegaly the basal GH levels are 
elevated and there is failure of GH suppression after an oral glucose load. This response 
is due to impaired somatostatin response or tumoral resistance to suppression by 
somatostatin (22). Post glucose suppression GH levels increase in one third of patients, 
remain unchanged in one third, or fall modestly in one third (23, 24).  The following are 
the criteria defining diagnosis of acromegaly (25) as proposed by the consensus statement 
in 2000.   
Random GH< 0.4 ug/l and normal IGF-1, excludes acromegaly 
GH nadir during OGTT <1 ug/l and normal IGF-1 excludes acromegaly. 
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Following a clinical and biochemical diagnosis of acromegaly, magnetic resonance 
imaging studies confirm the presence of a pituitary adenoma that is then classified as 
micro- or macro when they are <10 or >10 mm in maximum diameter.   MRI (26) is 
excellent in determining tumor invasion into the sphenoid sinus or cavernous sinuses and 
encasement of the internal carotid arteries all of which are factors that limit the extent of 
resection.    
 
PATHOLOGY AND CLINICAL CORRELATION 
 
The classification of GH adenomas into sparsely granulated (SG) and densely granulated 
(DG) types has been discussed earlier. Yamada et al (27) compared the clinical and 
endocrinological characteristics, neuroimaging findings, surgical outcome, and 
conventional histological findings (including immunohistochemistry) with the electron 
microscopic appearance of 31 growth hormone (GH)-producing adenomas. Sparsely 
granulated adenomas were found to more frequently affect younger women and also were 
more likely to be macroadenomas and invasive. The authors did not find any significant 
difference in the basal serum GH and insulin-like growth factor I levels. Light 
microscopy showed that densely granulated adenomas were mainly acidophilic and were 
immunopositive not only for GH but also for prolactin , the beta subunit of thyroid-
stimulating hormone and the alpha subunit of glycoprotein hormone, whereas SG 
adenomas were almost all chromophobic and only revealed immunopositivity for 
GH. Bhayana et al (28) concluded from their study that densely granulated somatotroph 
adenomas were more responsive to octreotide treatment.  
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Obari et al (29) in a study on 104 GH cell adenomas found that sparsely granulated 
variant was associated with younger age, higher frequency of macroadenomas and were 
more invasive.  
 
MORTALITY RATES IN ACROMEGALY 
Patients with biochemically uncontrolled acromegaly perform significantly worse on 
health related quality of life questionnaires than those in remission or discordant 
remission status (31). 
 
CARDIAC DISEASE 
Symptomatic cardiac disease is present in about 20% of patients and is a major cause of 
morbidity and mortality (32). Hypertension is present in about 50% of patients with 
active acromegaly, and half of these have evidence of left ventricular dysfunction. 
Cardiovascular disease accounts for about 60% of deaths in patients with acromegaly, 
and the presence of cardiovascular disease at the time of diagnosis portends high 
mortality rates, despite improved cardiac function after effective GH and IGF-I control. 
 
CANCER 
A compelling cause-and-effect relationship of acromegaly with cancer has not been 
established. A recent controlled study in 161 patients revealed no increase in colonic 
polyp incidence in acromegaly (33). Analysis of nine retrospective reports (1956-1998) 
encompassing 21,470 person-years at risk, yielded no significant increased cancer 
incidence (34). Orme et al (35) showed that mortality from colon cancer is largely related 
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to GH levels, rather than enhanced incidence of the disease in acromegaly. 
Cardiovascular disease, respiratory disorders, diabetes, and malignancy account for 
enhanced (threefold) mortality in acromegaly (32, 35). In 194 patients with acromegaly, 
life expectancy was reduced, and cardiovascular disorders accounted for 24% of deaths, 
followed by respiratory (18%) and cerebrovascular disease (14%).  
 
Diabetes mellitus, occurring in 20% of patients, was associated with 2.5 times the 
predicted mortality, and hypertension was present in about half of all patients. (36)   
 
WHAT DECIDES CRITERIA FOR CURE? 
 
Epidemiologic studies have shown that the high rates of morbidity and mortality 
associated with acromegaly can be greatly reduced by controlling GH levels (35-38, 40).  
But there is a difference of opinion about the GH levels to be attained.  Some long term 
follow-up studies after transsphenoidal surgery and adjunctive therapy for acromegaly 
show that regardless of the stringency of criteria for cure (< 5 ng/ml vs. < 2 ng/ml), the 
mortality rate achieved for those in remission was equivalent to that in matched controls, 
in contrast to the 2.4 – 4.8 fold enhanced mortality in those patients with persistent 
disease(40)  However, others argue that a random GH value of < 2 ng/ml was associated 
with a significantly lower mortality rate and should be regarded as an appropriate 
therapeutic target.(42)  Holdaway et al (32) followed up 208 patients for a mean of 13 
years studying the predictors of mortality with special reference to IGF-1 levels.   They 
confirmed that patients with acromegaly continue to have increased mortality rates 
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despite treatment but the standard mortality rate (SMR: ratio between observed and 
expected number of deaths) can be normalized by achieving serum GH concentrations 
less than 1 to 2 micrograms/ml and by normalizing IGF-1 levels.  One drawback of this 
study, is that the majority of patients received pituitary radiation as part of their treatment 
and this is likely to have contributed to the hypopituitarism seen in the treated group and 
may be a confounding factor in the analysis.  Interestingly, Lindholm et al (43) recently 
showed that pituitary insufficiency after surgery for nonfunctional pituitary adenomas 
had no effect on mortality in men but the SMR was significantly higher in women.  They 
speculate that the difference was likely to be due to insufficient gonadal replacements in 
women.  The effect of radiotherapy on mortality in acromegaly was also highlighted by 
Ayuk et al (42) who found that even after controlling for GH levels, patients who 
underwent radiation had increased mortality with cerebrovascular disease being the 
predominant cause of death.  These authors also found that younger patients may be at 
greater risk with persistent disease than older patients but that raised IGF-1 levels did not 
adequately predict mortality.   
 
PREDICTORS OF CURE: 
 
An ability to predict the long term outcome after surgery would help in initiating adjuvant 
therapy early. This can reduce the harmful effects of long term exposure to high GH 
levels. Both preoperative and post operative factors have been identified. The 
preoperative determinants include tumour size, preoperative GH concentration and the 
experience of the surgeon.    
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Valdemarsson et al (99) looked at the role of intraoperative GH levels in predicting long 
term of pituitary surgery. Venous blood samples for GH were drawn at the beginning of 
the operation and then intraoperatively, when the surgeon considered the tumour to have 
been removed (= 0min); and then 10, 20, 30, 40, 60, 90, 120 and 180min. To calculate a 
mean early postoperative GH level 5-7 blood samples were drawn on the 7th post 
operative day after surgery. The t 1/2 GH (Figure 2) was calculated from the intraoperative 
blood samples drawn at 0, 10, 20, 30 and 40min. Growth hormone elimination was 
assumed to follow first order kinetics and the slope of the graph between time and serum 
GH level was used to calculate the half life of GH. A calculated GH half life of <31 min 
had a positive predictive value of 72%. However they found that mean post operative GH 
at one week had a predictive value of 100% when <2.6 ng/ml. Another paper published 
by the same group (100) showed that a mean serum GH level of < 2 ng/ml sampled 
within the first postoperative week was found to have 77% specificity and a predictive 
value at 97% for a satisfactory effect with regard to the outcome of the operation as 
evaluated 3 months later (the definition of cure being post glucose suppression GH level 
of < 2 ng/ml or a normalized IGF-1).   
 
Multiple studies have shown that microadenomas have a much better remission rate as 
compared to macroadenomas. The remission rates using the current stringent criteria for 
microadenomas range from 75-100% whereas for macroadenomas the range is 21-78% 
(48, 51, 53, 56, 61, 62, and 64).  
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            Figure 2: Graph showing log (serial intraoperative GH measurements) versus time 
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Similarly Osman et al (94) found that a minimum GH of < or = 2 mU/l during an OGTT 
(oral glucose tolerance test) was achieved in 67.4% of patients with intrasellar tumours, 
compared with 27.3% with extrasellar tumours. 
 
Kaltsas et al (95) showed that patients who achieved remission had significantly lower 
preoperative mean GH levels than patients who were not cured (median, 31 mU/L vs. 
78.5 mU/L, P < 0.01).  
 
De et al (53) showed that if the preoperative GH level was < 10 ng/ml then there was 
86% chance of remission. Similarly Shimon et al (39) in their study showed only a 20% 
chance of remission if the preoperative GH level was more than 50 ng/ml.  
Shimon et al preop GH > 50 ng/ml only 20% chance for remission. 
 
Ahmed at al (48) and Lissett et al (59) demonstrated significant increase in the remission 
rates over time with increase in the surgeon’s experience.  
 
Bourdelot et al (96) listed the following predictors for poor outcome. High IGF-I 
concentration before surgery, young age, high basal GH concentration before surgery and 
high nadir GH/OGTT before surgery. The MRI predictors of poor outcome were: 
adenoma greater than 15mm in diameter, infrasellar extension, suprasellar extension and 
invasive adenoma. 
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Studies that looked at electron microscopy features of growth hormone adenomas found 
that sparsely granulated adenomas were more invasive and had lower surgical cure rates 
(27, 29). Densely granulated growth hormone adenomas were also found to be more 
responsive to octreotide treatment (28). 
 
The post operative factors which have been evaluated, include growth hormone levels 
and IGF-1 levels for assessing disease response to surgery and predicting long term 
remission. Most studies have used basal/random GH values as an indicator of disease 
activity and the response to surgery (40, 63, 67, 94, 97, and 98). 
 
Kaltsas et al (95) evaluated 67 patients with acromegaly. At 7 days following 
transsphenoidal surgery, GH secretion was assessed by calculating the mean serum GH 
from a five-point GH “day curve,” samples being collected at 0830 h, 1100 h, 1300 h, 
1700 h, and 1900 h. The authors took an early postoperative GH level of < 5ng/ml as 
"safe". Relying on a single GH measurement alone, 9 of the 23 patients with a single 
postoperative mean GH level less than 5 mU/L obtained at least one GH value of 
more than 5 mU/L (false positive rate, 28%) and 8 of the patients with a postoperative 
mean GH value of more than 5 mU/L obtained a single GH value of less than 5 mU/L 
(false negative rate, 15%), thus showing that early mean post operative GH levels were 
more sensitive as compared to random GH level. They suggested that mean serum GH 
levels and single IGF-I levels, measured early in the postoperative period, are currently 
the best biochemical guide to the adequacy of surgery and, hence, the need for further 
treatment. 
 30  
Takahashi et al (101) examined IGF-1 and glucose suppressed GH levels within the first 
postoperative month, and correlated it with cure at final follow-up (as documented by a 
normalized IGF-1 level). The mean follow-up period was 7 years, and they found that 
patients who attained both normalized IGF-1 and glucose suppressed GH < 1ng/ml, 
stayed cured. However, even in patients who did not meet both criteria within the first 
postoperative month, glucose-suppressed GH < 1.5 ng/ml, or glucose-suppressed GH < 4 
ng/ml coupled with early IGF-1 normalization indicated the possibility of cure. None of 
the patients with an early glucose-suppressed GH > 4 ng/ml, achieved cure. 
 
Feelders et al (102) did a prospective study with 1-yr follow-up on 17 patients who 
underwent transsphenoidal surgery for acromegaly. The outcome measures included 
OGTT at 1, 2, 3, 8, and 12 wks after transsphenoidal surgery; weekly measured GH,  
IGF-I and total IGF-I levels measured at 52 wks. According to the postoperative GH 
nadir, patients were classified into two groups using 1 ng/ml as the cutoff value. The nine 
patients, who were cured at one year, all had nadir GH levels in the first post operative 
week of 0.5 ng/ml or less. They concluded that 1 week post glucose suppressed GH level 
of 0.5 ng/ml or less had a high predictive value for cure. Because IGF-I showed varying 
patterns towards stabilization, they recommended against using it as a predictive 
parameter within 3 months after surgery. 
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TREATMENT OF GH-SECRETING PITUITARY ADENOMAS 
 
Definition of cure or remission in acromegaly 
 
The definition of cure in acromegaly has undergone several revisions over the years, each 
making the criteria more stringent with the development of more sensitive assays for GH 
and IGF-1. Various investigators have advocated the use of fasting GH levels, mean GH 
values of a series collected over 24 h, GH nadir during the first 2 hours following OGTT, 
or IGF-I levels to assess the outcome of treatment in acromegaly(107). Although IGF-I 
levels correlate well with clinical activity of acromegaly (55), they have been thought 
insufficient alone in predicting the long-term benefits of surgery (16). This view was 
supported by Sheaves et al. (65), who favored a combination of a GH day profile and 
IGF-I levels in the follow-up of treated patients with acromegaly. Puder et al (44) have 
shown that in the presence of discordant nadir GH and IGF-1 values, IGF-1 was a better 
predictor of disease control than random/post suppressed GH values. The study was 
based on insulin sensitivity as an indicator of disease control. Insulin resistance is a very 
common metabolic abnormality in patients with active acromegaly and is a major 
contributor to the increased cardiovascular risk associated with this disease. Buchfelder et 
al. (105) and Stoffel-Wagner et al. (106) have demonstrated that a nadir GH level of less 
than 1.0 ng/ml during OGTT provides much better prognostic information than random 
GH measurements in determining remission of acromegaly. Most recently, Giustina et al 
(25) have provided good evidence that, in addition to a mean random GH level below 2.5 
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ng/ml, treatment goals should restore GH levels to less than 1.0 ng/ml during an OGTT 
and normalize age- and gender-related IGF-I levels.(Consensus statement, 2000). 
 
When to assess for cure? 
The timing of postoperative testing may also be important, and recent evidence from 
Kaltsas et al, (95) suggests that early assessment may be as effective as more traditional 
analyses in which formal testing of the GH axis is delayed until 1 month or more after 
surgery. They found no differences in remission rates assessed at 1–3 wk compared with 
more than 4 wk after surgery and propose that early measurement of IGF-I is 
prognostically useful. This is in contrast to others who have suggested that early 
postoperative analysis may be inaccurate (25). However IGF-1 as an indicator of cure is 
significant at 3 or more months after surgery (102). 
 
 
Surgery: 
The overwhelming advantage of surgery over other modalities of therapy is the prompt 
reduction in tumor volume and relief of chiasmal compression.   Currently, surgery is still 
considered to be the first line treatment for acromegaly and medical/radiation therapies 
are considered adjuncts should surgery fail (45).  Transsphenoidal surgery is the 
procedure of choice and craniotomy is very rarely indicated. In microadenomas, complete 
adenomectomy with preservation of normal adenohypophysis is recommended. In 
macroadenomas, radical surgery is the goal, recognizing that a peripherally located tumor 
capsule represents normal adenohypophysis (103).  In patients who fail to achieve 
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surgical cure, reoperation for surgically accessible residual or recurrent tumor seen on 
MRI should be considered (45).  
 
Results of surgery 
Cure rates:    Several recent series have reported on the results of transsphenoidal surgery.  
Symptomatic relief occurs in nearly 95% of cases (68). Cure rates with the stringent 
criteria of nadir GH levels < 1.0 ng/ml during a GTT vary from 35.5% to 84.4% (see 
table 2). With less strict criteria the remission rates are higher: 76% when < 5 ng/ml GH 
levels were used (46) to 94% when < 10 ng/ml was the criterion for cure (47).  
Table 2. compares the results of transsphenoidal surgery for acromegaly in literature. 
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Table:2 
PRIMARY TRANSSPHENOIDAL SURGERY FOR GH-SECRETING PITUITARY 
ADENOMA 
 
     
 
 
    Series 
 
 
 
Number of 
Cases 
 
 
 
Total 
Cure Rate 
(%) 
 
 
 
Microadenomas    
(%) 
 
 
 
 
 
Macroadenomas 
(% 
 
 
 
Definition of 
Cure 
Davis et al, 
1993(52) 
     174      52         N/A           N/A GH <2 ng/ml 
(<4 mU/I; 
basal or 
OGTT) 
Sheaves et 
al, 1996(65) 
    100      42          61            23 GH <2.5 
ng/ml (<5 
mU/I) 
Swearingen 
et al, 
1998(66) 
    162      57         91           48 Normal IGF-
I levels 
Lissett et al, 
1998(59) 
     73     18         39            12 GH <5 ng/ml 
after OGTT 
 
 35  
 
     
 
 
    Series 
 
 
 
Number of 
Cases 
 
 
 
Total 
Cure Rate 
(%) 
 
 
 
Microadenomas    
(%) 
 
 
 
 
 
Macroadenomas 
(% 
 
 
 
Definition 
of Cure 
Abosch et 
al, 1998 
(40) 
     254      76            75             71 GH <5 ng/ml 
(<10 mU/I) 
Ahmed et 
al, 
1999(48) 
      97      —           90             56 Basal GH 
≤2.5 ng/ml  
(<5 mU/I), 
OGTT GH 
<1 ng/ml (<2 
mU/I), 
normal IGF-
I levels 
Biermasz 
et al, 
2000(49) 
      59     41           NA            NA Basal GH ≤ 
2.5 ng/ml 
(<5 mU/I) 
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    Series 
 
 
 
Number of 
Cases 
 
 
 
Total Cure 
Rate (%) 
 
 
 
Microadenomas    
(%) 
 
 
 
 
 
Macroadenomas 
(% 
 
 
 
Definition of 
Cure 
Laws et al, 
2000(58) 
       117        67           87              51 Basal GH 
<2.5 ng/ml 
(<5 mU/I), 
OGTT GH <1 
ng/ml (<2 
mU/I), 
normal IGF-
levels) 
Fahlbusch, 
2001(41) 
     490        56            78             50 Basal GH <5 
ng/ml (<10 
mU/I), OGTT 
GH <2 ng/ml 
(<4 mU/I), 
normal IGF-I 
levels 
Kreutzer et 
al, 2001(57) 
       57      70.2           NA            NA OGTT GH <1 
ng/ml (<2 
mU/I) 
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    Series 
 
 
 
Number of 
Cases 
 
 
 
Total Cure 
Rate (%) 
 
 
 
Microadenomas    
(%) 
 
 
 
 
 
Macroadenomas 
(% 
 
 
 
Definition of 
Cure 
De et al, 
2003(53) 
       90       63            79            56 OGTT GH 
<1 ng/ml (<2 
mU/I), 
normal IGF-
levels 
Minniti et 
al, 2003(61) 
      92      55           80           50 OGTT GH 
<1 ng/ml (<2 
mU/I), 
normal IGF-
levels 
De et al, 
2003(53) 
      90        63          79           56 OGTT GH 
<1 ng/ml (<2 
mU/I), 
normal IGF-
levels 
Nomikos et 
al, 2005(62) 
      668       57.3          75.3           50.3 OGTT GH 
<1 ng/ml (<2 
mU/I), 
normal IGF-
levels  
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    Series 
 
 
 
Number of 
Cases 
 
 
 
Total Cure 
Rate (%) 
 
 
 
Microadenomas    
(%) 
 
 
 
 
 
Macroadenomas 
(% 
 
 
 
Definition of 
Cure 
Abbasioun et 
al, 2006(47) 
      104       94.2           NA           NA Basal GH< 10 
ng/ml 
Boeving et 
al, 2006(50) 
      28       35.5          NA          NA Basal GH 
≤2.5 ng/ml 
(<5 mU/I), 
OGTT GH <1 
ng/ml (<2 
mU/I), normal 
IGF-I levels  
Boeving et 
al, 2006(50) 
       28       35.5           NA            NA Basal GH 
≤2.5 ng/ml 
(<5 mU/I), 
OGTT GH <1 
ng/ml (<2 
mU/I), normal 
IGF-I levels  
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    Series 
 
 
 
Number of 
Cases 
 
 
 
Total Cure 
Rate (%) 
 
 
 
Microadenomas    
(%) 
 
 
 
 
 
Macroadenomas 
(% 
 
 
 
Definition of 
Cure 
Santoro et al, 
2007(64) 
       109        61            85               55 OGTT GH <1 
ng/ml (<2 
mU/I), normal 
IGF-levels 
Gondim et al, 
2008(56) 
       33      84.84           100          78.2 OGTT GH <1 
ng/ml (<2 
mU/I), normal 
IGF-levels 
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Many studies have assessed recurrence rates after transsphenoidal surgery for 
acromegaly, but these rates vary considerably, possibly because of lack of uniformity in 
the criteria used to define remission.   It is likely that older studies overestimated the cure 
rates due to the lack of precise GH assays. Modern series with long-term follow-up, 
report recurrence rates between 1.1 and 19% (57, 40, 49, and 66).  Freda et al (69) studied 
110 postoperative patients with acromegaly and defined remission by normal IGF-1 
levels.  The 76 patients who were in remission were divided into two groups – Group 1 
were those with nadir post-suppression GH levels < 0.14 ng/ml and Group II were those 
with nadir post-suppression levels >0.14 ng/ml.   Group I patients continued to be in 
remission on long-term follow-up however, 5 of the 19 patients in Group II were found to 
have elevated IGF-1 levels 2 to 6 years after surgery and were diagnosed to have 
biochemical recurrence.  They concluded that those patients in remission postoperatively 
who have a subtle failure of normal GH suppression have additional evidence of 
relatively increased GH secretion compared with those patients with normal GH 
suppression.   They suggest that as long as IGF-1 normalization is maintained, these 
patients can be observed without additional therapy.   However, with longitudinal follow-
up, abnormal GH nadir was associated with a higher rate of disease recurrence as defined 
by the development of elevation in IGF-1 levels and these patients may need to be 
monitored more closely for recurrence. 
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Presurgical treatment with somatostatin analogs: 
The evidence that preoperative GH level, tumor size and invasiveness contributed to 
outcome prompted the use of perioperative pharmacotherapy to enhance results of 
surgery (70).  Colao et al (71) showed that surgical debulking helped in increasing 
remission rates from 12% to 76% in patients harboring invasive tumors that responded 
poorly to primary medical therapy, that is, somatostatin analogs, for at least 6 months 
before surgery.  On the other hand, in a recently performed large case-controlled study 
(72), 143 patients who received somatostatin analogs for 3 months before surgery (Group 
I) were matched for tumor size and invasiveness with 143 patients who had direct surgery 
without pharmacotherapy (Group II).   Although there was a 50% reduction in GH levels 
with medical therapy in 64% of cases before surgery in Group I, the overall surgical 
remission rate was 57% in group I and 64% in Group II.   The conclusion was that 
pretreatment with somatostatin analogs (octreotide, lanreotide or octreotide LAR) did not 
provide any benefit in cure rates after surgery. However the study by Carlsen et al (73) 
shows better cure rates with somatostatin analog pretreatment. They randomized 61 
newly diagnosed acromegalics into two groups- direct transsphenoidal surgery (n=30) or 
pretreatment with octreotide (n=31) 20mg intramuscularly every 28th day for 6 months 
before transsphenoidal surgery. Cure was evaluated 3 months postoperatively primarily 
by normalized IGF-I levels. 14 of 31(45%) pretreated patients vs. seven of 30 (23%) 
patients with direct surgery were cured. In patients with microadenomas (<10 mm), one 
of five (20%) pretreated vs. three of five (60%) with direct surgery were cured. In 
patients with macroadenomas, 13 of 26 (50%) pretreated vs. four of 25 (16%) with direct 
surgery were cured. 
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Radiotherapy 
The role of radiotherapy (RT) in acromegaly is almost entirely restricted to those patients 
who fail previous surgery, since pituitary dysfunction and delay to remission limit its 
utility.  As primary therapy, conventional RT is known to reduce tumor mass, GH levels 
and pituitary function predictably with time. Further growth is prevented in 99% of 
patients; GH levels progressively decrease to 50% of baseline by 2 years and 75% of 
baseline by 5 years.  Further decrease in GH levels are seen at 10 and 15 years and 90% 
of those surviving at 15 years have levels < 5 ng/ml.  Using more stringent criteria of 
cure, post suppression GH levels < 1ng/ml after a GTT, were seen in 9% of patients at 2 
years, 29% at 5 years, 52% at 10 years and 77% at 15 years when radiation was used as 
an adjunct to surgery (74). Fifty percent of patients who underwent treatment with both 
radiation therapy and surgery have reported hypopituitarism, and the incidence can 
increase with time from exposure for up to 20 years post treatment (75, 76). Minniti et al 
(74) noted progressive hypopituitarism, which was present in 33% of patients at baseline 
and increased to 57%, 78% and in 85% of patients at 5 10 and 15 years after RT, 
respectively. 
 
Fractionated conformal stereotactic radiotherapy in patients with residual or recurrent 
tumors, achieves tumor control and normalization of GH levels at rates comparable to 
conventional RT (77). Moreover, the rate of decline and normalization of GH levels are 
within the same reported range following conventional RT. Delayed hypopituitarism is 
still a problem with incidence varying from 5% to 29% (77-79) depending on the 
duration of follow-up.   
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Gamma knife radiosurgery (GKS) for acromegaly appears to show promising results but 
long-term follow-up is necessary to ascertain the incidence of hypopituitarism (80, 81).    
Witt et al (82) reviewed 20 different radiosurgery studies published between 1997 and 
2002 and found that tumor control in acromegaly ranged from 68 to 100%. He also found 
endocrine improvement in 0 to 67%, depending on the study. The endocrine cure in the 
different studies ranged from 0 to 96%. Zheng et al (83) used GKS as primary therapy for 
acromegaly in 68 patients, which constituted 80% of their cases and had a follow up for a 
mean of 34 months.  They do not define their criteria of cure but mention that 
“normalization of the hormonal levels” was achieved in 23 (40%) of 58 patients followed 
for 12 months, and in 96% of cases followed for more than 24 months.  One patient with 
an invasive tumor developed bilateral 3rd nerve palsies that recovered in 6 months and 
another patient had reduced visual acuity one year after GKS.  No details are available for 
incidence of hypopituitarism.   Jezkova et al (84) suggest that GKS is a useful adjunct to 
surgery in acromegaly when treating residual tumor and recommend its use as primary 
therapy only when surgery is not possible. The majority of their patients (75%) had 
previous surgery and only 25% were treated primarily with GKS with normalization 
intervals shorter than in conventional RT.  They used three different criteria to establish a 
successful outcome, but the results of the most commonly accepted criterion, post 
suppression GH levels < 1ng/ml in an oral GTT and normal IGF-1 levels a median 
interval to normalization of 66 months the percentage of patients achieving a cure at 1, 3, 
5 and 8 years was 14.6%, 28.6%, 44.2% and 57.1% respectively.  They noted that 32% of 
patients developed thyroid hormone deficiency, 14% adrenal insufficiency and 41% 
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gonadal deficiency.  Losa et al (85) looked at stereotactic radiosurgery without 
concomitant GH-suppressive drugs in 83 patients with residual or recurrent GH-secreting 
adenomas. The rate of remission (GH level < 2.5 ng/ml) was 52.6% at 5 years. The 5-yr 
cumulative risk of new onset hypogonadism, hypothyroidism, or hypoadrenalism was 
3.6%, 3.3% and 4.9% respectively. 
 
Medical Therapy 
Dopamine agonists, such as bromocriptine and cabergoline, reduce basal GH to < 5ng/ml 
in only 10-30% of cases and normalize IGF-1 levels in <10% (86).   There are some 
reports that mixed GH-PRL tumors respond better to dopamine agonists (86). These are 
relatively cheap drugs and may have some role in the postoperative treatment of patients 
with residual disease.   Somatostatin analogues are more effective than dopamine 
agonists and studies have convincingly shown their efficacy on hormonal levels and 
tumor size (87). These drugs were used as adjuvant therapy alone but have been 
employed as primary treatment when financial constraints do not exist.(88)  In a 
prospective long-term follow-up study, Cozzi et al (89) treated 67 naive patients with 
acromegaly with octreotide LAR but 33 patients elected to undergo other forms of 
therapy during the study.  Their outcome measures were basal GH (<2.5 ng/ml), normal 
IGF-1 levels and tumor shrinkage.  GH and IGF-1 levels decreased mostly within 6-12 
months but progressive declines resulted in hormonal endpoints in 57% of patients.   Five 
percent of patients were unresponsive to treatment, that is, < 10% change in GH/IGF-1 
levels in 6 months.   Pretreatment GH levels made no difference to the outcome.   Tumors 
shrank in 82% of patients within 6 months and continued to decrease in size.  
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Macroadenomas tended to show a more impressive response than microadenomas with 
>50% size reduction in 70% of cases, though two of three tumors that disappeared were 
microadenomas.  Invasiveness, however was not reverted, though in a few cases those 
tumors that showed doubtful invasion proved to have clear borders separate from the 
cavernous sinus wall with treatment. These findings are supported by more recent studies 
(90) that have shown significant tumor size reduction and GH normalization at 6 months; 
though the results were worse for macroadenomas with only 45% of patients achieving 
GH levels < 2.5 ng/ml.   At the present time, surgery and medical therapy complement 
each other in the overall management of acromegaly.   Recent data points towards a role 
for surgical debulking in improving response to somatostatin agonists in tumors that are 
only partially sensitive to these drugs (71, 91).  
The disadvantages of octreotide are that it tends to produce gastrointestinal side effects 
and predisposes to the development of gallstones.   While it requires thrice-daily 
subcutaneous injections, long acting formulations of somatostatin analogs (octreotide 
LAR and lanreotide) are as effective but some patients may not respond to these drugs 
optimally or become intolerant. 
Pegvisomant, the first recombinant GH-receptor antagonist, does not inhibit the 
production of GH but binds at peripheral GH receptors and prevents IGF-1 production.  
Therefore its action is independent of tumor characteristics such as size and invasiveness 
and it effectively normalizes IGF-1 levels in 70% of patients by 12 months (92). Since 
pegvisomant is detected in conventional GH assays, it may result in falsely high 
estimation of serum GH concentrations; therefore its efficacy can be monitored only by 
IGF-1 levels and not by GH levels.   Furthermore, some tumors can in fact grow while on 
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treatment with this drug therefore patients need to be monitored for visual deterioration 
and tumor growth on MRI.  The efficacy of pegvisomant is dose dependent and IGF-1 
levels have been normalized in those patients who were surgical failures or who were 
resistant to or intolerant of somatostatin analogs (93).  
 
Table 3. compares the advantages and disadvantages of the various treatment modalities 
for acromegaly. 
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Table 3- Various treatment modalities in acromegaly. 
 
Characteristic Surgery 
Radiation 
Therapy SRL 
GHR 
Antagonist 
Dopamine 
Agonist 
Advantages 
Mode Transsphenoidal 
resection 
Noninvasive Monthly 
injection 
Daily 
injection 
increases 
Oral 
GH <2.5 µg/L Macros <50% 35% in 10 yr 80%   <15% 
  Micros >80%         
IGF-I 
normalized 
  <30% >70% >90% <15% 
Onset Rapid Slow (years) Rapid Rapid Slow 
(weeks) 
Patient 
compliance 
Onetime 
consent 
Good Must be 
sustained 
Must be 
sustained 
Good 
Tumor mass Debulked or 
resected 
Ablated Growth 
constrained 
or shrinks 
<50% 
Unknown Unchanged
Disadvantages 
Cost One time One time Ongoing Ongoing Ongoing 
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Characteristic Surgery 
Radiation 
Therapy SRL 
GHR 
Antagonist 
Dopamine 
Agonist 
Hypopituitarism <10% >50% None Very low None 
        IGF-I if 
overtreated 
  
Other Tumor 
persistence or 
recurrence 6% 
Local nerve 
damage 2nd 
brain tumor 
Gallstones 
20% 
Elevated 
liver 
enzymes 
(rare) 
Nausea 
30% 
  Diabetes 
insipidus 3% 
Nausea, 
diarrhea 
  Sinusitis 
  Local 
complications 
5% 
Visual and 
CNS disorders, 
2% 
cerebrovascular 
risk 
    High dose 
required 
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MATERIALS AND METHODS: 
 
Study design:  
Retrospective analysis of a prospectively maintained database. 
 
Study population:  
Patients with acromegaly who underwent transsphenoidal surgery at the Department of 
Neurosurgery from the time period May 2001 till January 2007. 
 
The patient information was recorded in a proforma (Appendix-1) which included patient 
details, pre- operative, intraoperative and post operative data along with details of follow-
up. 
All patients had a complete hormonal evaluation and magnetic resonance imaging of the 
brain.  
Tumors were classified as microadenomas when they were <10 mm and macroadenomas 
were those that were 10 mm or larger.  Wilson’s modification (104) of Hardy’s staging 
system graded the macroadenomas into A, B, C, D or E.  Invasion was defined as 
involvement of the cavernous sinuses, sphenoid sinus or intraoperative evidence of dural 
invasion.    
Criteria for preoperative diagnosis of acromegaly: 
1. Clinical evaluation 
2. Elevated basal serum growth hormone levels of > 2.5 ng/ml 
3. Failure of growth hormone level to suppress below < 2 ng/ml following a glucose load                                
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(100 gm) 
4. Histopathology reported as Growth hormone secreting pituitary adenoma. 
 
Early post operative serum growth hormone levels were measured on the first morning 
after surgery (basal level) and seventh day (post suppression with 100 mg oral glucose) 
following transsphenoidal surgery. 
The GH hormone assay was done on Immulite-2000 using a Diagnostic Products 
Corporation kit. It is a solid phase, 2-site chemiluminescent immunometric assay, using 
murine monoclonal anti-HGH antibody and rabbit polyclonal anti-HGH antibody, 
conjugated to alkaline phosphatase. The sensitivity of the assay is 0.01 ng/ml with 
linearity upto 40 ng/ml. 
 
Histopathological evaluation included immunostaining for cytokeratin to classify the 
growth hormone secreting adenomas into sparsely/densely granulated adenomas. The 
detailed histopathological methodology is enumerated in Appendix-2. 
 
The patients were evaluated at follow-up with glucose suppressed serum growth hormone 
level measurements and IGF-1 after July 2004. The IGF-1 assay was done on Immulite-
2000 using a Diagnostic Products Corporation kit. It is a solid phase, 2-site 
chemiluminescent immunometric assay, using murine monoclonal anti-IGF-1 antibody 
and rabbit polyclonal anti-IGF-1 antibody, conjugated to alkaline phosphatase. The 
sensitivity of the assay is 20 ng/ml. The reference adult ranges are given in Appendix-3. 
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Criteria for remission: 
1. Glucose suppressed serum growth hormone level of less than 1 ng/ml. 
2. IgF-1 level in the normal range for age (IgF-1 levels were available and standardized at 
our institution only after July 2004). 
 
 
Analysis: 
The patients who had follow-up were included in the analysis and the following 
predictors of cure were evaluated – duration of symptoms, preoperative GH levels, size 
of tumour, Hardy’s grade, invasiveness, extent of excision, electron microscopy findings 
on histopathology and the main focus being on early post operative GH levels.  
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RESULTS: 
 
A total of 72 patients underwent transsphenoidal surgery for acromegaly between May 
2001 till January 2007. Their ages ranged from 16 to 75 years (mean 37.5) and there were 
36 women and 36 men.  Three patients did not have clinical features of acromegaly, the 
diagnosis being made on biochemical and immunohistochemical basis.   In the remaining 
69 patients, the duration of acromegaly ranged from 3 months to 15 years (mean 52 
months).   Preoperative vision was affected in 25 cases (35%).    Twenty five (35%) 
patients had diabetes, 27 (37%) had hypertension (HT) and 13 (18%) had both HT and 
diabetes.  There were 6 microadenomas and the remaining 66 were larger than 10 mm.  
Of the macroadenomas, 16 were Hardy’s stage A, 16 Stage B, 23 Stage C, 5 Stage D and 
6 Stage E. Mixed GH-PRL tumors were seen in 16 patients. Immunostaining for 
cytokeratin was available for 67 out of the 72 patients and in 52 of the 56 patients with 
follow-up. Based on the immunostaining for cytokeratin, tumours were classified into 
sparsely or densely granulated somatotroph adenomas. In the 52 patients, 25 patients had 
sparsely granulated growth hormone adenomas and the rest were densely granulated.  
 
The mean preoperative GH level was 34 ng/ml. Based on the preoperative basal GH 
levels, the patients were divided into two groups. The GH levels were <= 34 in 42 cases; 
> 34 in 30 cases.   The GH levels in the 6 microadenomas were <= 34 in 5 cases and > 34 
in 1 patient.  Twenty seven cases out of the 72 were found to be invasive either on the 
MRI or at surgery. In the 56 cases with follow-up the proportion of invasive tumours was 
20/56 (35.7%). 
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Follow-up was available in 56 patients (77.77%) ranging from 3 months to 65 months 
(median 21 months).    
 
5 out of the 56 patients were microadenomas and the remainder were macroadenomas. 
(Figure 3) 
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Bar diagram showing distribution of microadenomas and 
macroadenomas. 
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Early post operative GH levels as a predictor of cure: 
The 1st post operative day GH levels were available in 45 patients and the 7th post 
operative day GH levels were available in 40 patients. These values were evaluated to 
find out the early post operative GH level which would serve as a good indicator of cure. 
Initially a ROC (receiver operating characteristic) curve was used to plot the values and 
find out the GH level with the highest sensitivity and specificity. However, during the 
analysis it was found the area under the ROC curve was not significant because of the 
small number of patients. Hence ROC could not be used to find the specific GH level 
which was a good indicator of cure. Most of the adenomas which had been cured, had 
early GH values below 5 ng/ml. Hence we calculated the specificity and sensitivity of 
values from 1 – 5 ng/ml separately for predicting a cure. Statistical analysis was done 
using the 2 x 2 table. It was found that for both the first post operative day and the 
seventh post operative day, a value of 2 ng/ml yielded the greatest specificity and 
sensitivity. 
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1st post operative day GH level (Figure 4) of > 2 ng/ml had a negative predictive value 
(NPV) of 96.4%, positive predictive value (PPV) of 76.4%, sensitivity of 92.85% and a 
specificity of 87.1%. The P value was <0.05.  
 
This meant that if a patient who underwent transsphenoidal surgery for acromegaly, has a 
1st postoperative day GH level of more than 2 ng/ml, it is almost certain that he won’t be 
cured (NPV of 96.4%). Similarly if the value is less than 2 ng/ml, then he has a high 
chance of cure (PPV of 76.4%). That this test is significant is confirmed by the high 
sensitivity and specificity.  
 
Similarly the 7th post operative day GH level (Figure 5)   of > 2ng/ml had a negative 
predictive value of 88.36%, positive predictive value of 72.5%, sensitivity of 81.25% and 
specificity of 79.16%. The P value was <0.05. 
Thus, similar to the 1st postoperative day value, the 7th postoperative day value of more 
than 2 ng/ml was associated with high chance of failure and a value of less than 2 ng/ml 
correlated to a high chance of  cure. Here again the sensitivity and specificity were 
significant.  
 
Thus, the analysis showed that early postoperative GH levels were a good predictor of 
cure with a high specificity and sensitivity. 
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274
113
1st postoperative day basal               
GH level vs. remission
<2 ng/ml >2 ng/ml
YES
NO
GH Level
Remission
Negative predictive value 96.4%
Postive predictive value 76.4%
Sensitivity 92.85%
Specificity 87.1%
P value <0.05
Figure 4.
n=45
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313
7th postoperative day glucose suppressed   
GH level vs. remission
<2 ng/ml >2 ng/ml
YES
NO
GH Level
Remission
Negative predictive value 86.36%
Postive predictive value 72.5%
Sensitivity 81.25%
Specificity 79.16%
P value <0.05
Figure 5.
n=40
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Other predictors: 
 
The remission rates based on Hardy’s grade: (Figure 6) 
 
Microadenoma: 60% (3/5) 
 
Grade A- 35.7% (5/14) 
Grade B- 54.5% (6/11) 
Grade C- 47% (8/17) 
Grade D- 25% (1/4) 
Grade E- 0% (0/6) 
The p-value on a Chi square test for determining the significance of size was 0.45 with 
lower Hardy’s grade (A,B,C) having an odd’s ratio of 6.61 for cure.  
  
 
Remission with relation to preoperative random GH value: (Figure 7) 
 
The patients were divided into 2 groups based on the mean preoperative GH level.  
 
19 of the 33 patients with GH level < 34 ng/ml were in remission (57.6%) whereas only 4 
out of the 23 patients with GH level > 34 ng/ml were in remission (17.4%). The p-value 
on a Chi square test was 0.0002 which was significant. 
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Remission rates based on size
Figure 6
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Remission rates and invasiveness: 
 
In the non-invasive adenomas, the overall cure rate was 44.4% (16 out of 36 patients), 
whereas in the invasive group, the cure rate was 35% (7 out of 20 patients). The p-value 
was 0.49. 
 
Remission rates and duration of symptoms: 
Based on the duration of symptoms, the patients were divided into 2 groups. Patients with 
duration of symptoms less than 24 months had an overall cure rate of 41% (7 out of 17 
patients). Patients with duration of symptoms more than 24 months had the same cure 
rate of 41% (16 out of 39 patients). The p-value was 0.99. 
 
 
Remission rates association with immunostaining characteristics: 
Immunostaining for cytokeratin to classify tumours into sparsely and densely granulated 
variants, was available in 52/56 patients. In the 52 patients, 25 patients had sparsely 
granulated growth hormone adenomas and the rest of the 27 patients were densely 
granulated. 6/25 of the patients with sparsely granulated variety were in remission as 
compared to 8/27 in the densely granulated category. The p-value was 0.64. 
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Table 4 shows the results of the univariate analysis for each variable for predicting a cure.  
Included in the analysis are 56 patients who had follow-up GH levels.   A univariate 
analysis was performed using the variables: duration of symptoms, preoperative GH 
levels, size of tumor, Hardy’s stage, invasiveness, extent of excision and whether the 
tumour was sparsely granulated or not. These were compared with the outcome variables 
– cure or failure (cure- glucose suppressed level of GH < 1 ng/ml).  Duration of 
symptoms more than 24 months had an Odd’s ratio of predicting non-remission of 1.01. 
Macroadenomas were 2.33 times likely to have non-remission as compared to 
microadenomas. Invasiveness was found to be not significant in predicting the outcome 
(Odd’s ratio of 0.67). A radical excision of the adenoma had a 2 times greater chance of 
remission as compared to non-remission. Electron microscopy findings (sparsely 
granulated adenomas) also were not significant in predicting cure (Odd’s ratio of 0.75). 
 
Preoperative growth hormone level of < 34 ng/ml meant that there was a 6.45 times 
greater possibility of cure as against a level of > 34 ng/ml. (95% CI 1.56-28.78, p-value 
0.002). 
 
Similarly, a lower Hardy’s grade of tumour (A, B, C) had a 6.61 times of remission as 
compared to Hardy’s grade D or E tumours (95% CI 0.71-153.6, p-value 0.45). 
 
Hence preoperative GH level was the most significant factor associated with a cure. 
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Predictor variables Cure =23 Failure=33
Odds ratio 95% CI P-vALUE
Duration of 
Symptoms
<24 months
>24 months
7 10
16 23
1.01 0.27-3.7 0.99
0.002
0.33
0.45
0.49
0.27
1.56-27.78
0.28-3.38
0.71-153.6
0.91-2.39
0.48-9.42
6.45
2.33
6.61
0.67
2.0723
14
19
2
31
23
8
13
20
10
19
4
3
20
19
1
7
16
19
4
<34ng/ml
>34ng/ml
Microadenoma
Macroadenoma
A,B,C
D,E
Invasive
Noninvasive
Radical
Sub-total
Preoperative
GH values
Size of
Tumor
Hardy’s
Grade
Invasive-
ness
Extent of
excision
Immuno
Histochemistry
Sparsely
granulated
Outcome variables
YES
NO
6 19
8 19
0.75 0.18-3.03 0.64
Table 4
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Cure rates and multimodality treatment: 
At follow-up, based on nadir post glucose suppression GH levels, sixteen patients 
(28.5%) were in remission after surgery (mean follow-up 20 months), while 40 (71.5%) 
were surgical failures. The 40 patients who were in non-remission were kept on close 
follow-up, started on medical therapy, radiation therapy or underwent second surgery.  
 
Of the fifty six patients, 2 underwent a second surgery and 13 patients received radiation 
therapy (11-SRT, 2-Conventional). One more patient went into remission after 2 
surgeries, one after 2 surgeries and radiation therapy, 2 patients after surgery and 
radiation therapy and 4 patients with surgery and medical therapy (dopamine agonists). 
Therefore the final cure rate of initial surgery + 2nd surgery + RT + Medical therapy was 
23/56 (41%). A total of 33 patients were still not in remission after multi-modality 
treatment. 
 
Interestingly, when IGF-1 was used in isolation, as criterion for remission , the cure rates 
were much higher. IGF-1 was available in 42 of the 56 patients with follow-up. 30 out of 
the 42 patients were in remission (71.42 %). In this group, there was a subset (8 patients), 
whose post glucose suppressed serum growth hormone levels were more than 1 ng/ml but 
less than 5 ng/ml. Post glucose suppressed GH values of < 5 ng/ml have been considered 
safe enough to lower mortality rates to expected levels (38). Hence, although not 
adhering to the stringent criteria, these patients with a normalized IGF-1 and GH level 
between 1-5 ng/ml could be considered to be in partial remission. The various treatment 
modalities used in the patient management are depicted in Figure 8. 
 66  
N=56
Remission =23 Non-Remission=33
Surgery
16
Surgery +
Cabergoline/RT
/2 SURGERIES
7
Remission:  Glucose suppressed GH level < 1 ng/ml
( All the values are glucose suppressed GH levels )
Cabergoline Resurgery Radiation therapy
Follow up 
Figure 8.
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CASE REPORTS: 
 
These case reports show the varied response to surgery and the multimodality treatment 
that is required for cure of this difficult disease. 
 
Case 1: (Figures 9, 10) 
 
This 38 year old lady presented with acromegalic features and investigation revealed a 
Hardy’s grade B pituitary macroadenoma. She was not a diabetic or hypertensive. Vision 
was normal. She was on Tab. Eltroxine. The preoperative GH level was 8.9 ng/ml. She 
underwent transsphenoidal radical excision of the tumour. The next day GH was 0.8 
ng/ml and the 7th day value was 1.6 ng/ml. At 5 years follow-up, she continues to be in 
remission, with the GH level of 0.646 ng/ml and normalized IGF-1 level (117 ng/ml).  
She was still on Tab. Eltroxine.  
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Fig 9 (Case 1): MRI (T1 coronal with gadolinium) showing a grade B pituitary adenoma      
 
 
 
 
 
 
 
 
 
 69  
Patient 1 (Preoperative GH value: 8.9 ng/ml)
1.6
0.5
0.86
0.646
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 500 1000 1500 2000
G
H
 le
ve
l (
ng
/m
l)
(4 months) (16 months) (60 months)(32 months) (56 months)
(Post operative follow-ups)
7th day
4th Month
16th Month
60th Month
Figure 10
 
 70  
Case 2: (Figures 11, 12) 
 
This 39 year old lady presented with acromegalic features for 3 years. Her vision was 
normal and she was a hypertensive on medication. MRI showed a Hardy’s grade A 
macroadenoma with invasion of the sphenoid sinus. She was on both Tab. Prednisolone 
and Tab. Eltroxine as replacements. The preoperative GH level was 11.3 ng/ml. She 
underwent radical excision of the pituitary adenoma. The histopathology was reported as 
sparsely granulated GH adenoma. The 1st post operative day GH level was 4.35 and the 
7th post operative day GH level was 2.36 ng/ml. Her GH level continued to fall at follow-
up but at 22 months, it rose to 3.48 ng/ml. She was started on Tab. Cabergoline and at last 
follow up (36 months), she was in remission with a GH level of 0.747 ng/ml and an IGF-
1 level of 189 ng/ml (normal for age and gender). She continued to be on Tab. Eltroxine, 
Tab. Amlodipine for blood pressure and Tab. Cabergoline.  
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Fig 11(Case 2): MRI (T1 coronal with gadolinium) showing a grade A pituitary   
macroadenoma with sphenoid sinus invasion. 
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Figure 12
(Post operative follow-ups)
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Case 3: (Figures 13, 14, 15) 
 
This 44 year old male presented with acromegalic features. The preoperative GH level 
was 66.3 ng/ml. MRI showed a microadenoma but there was invasion into the right 
cavernous sinus. He was a hypertensive on medication. The cortisol and thyroid axes 
were normal. He underwent radical excision including the portion in the cavernous sinus. 
The 7th post operative day GH level was 2.1 ng/ml. However his GH level continued to 
rise at serial follow-ups. MRI brain did not show any residual tumour. He underwent 
Stereotactic radiation therapy one and half years after surgery. At last follow-up (5 
years), his GH level had decreased to 1.3 ng/ml and the IGF-1 was normalized for age 
and gender (105 ng/ml). 
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Fig 13(Case 3): MRI (T1 coronal with gadolinium) showing a pituitary microadenoma 
with invasion of the right cavernous sinus.   
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Fig 14(Case 3): Post operative MRI at 8 months following surgery (T1 coronal with 
gadolinium) not showing any residual tumour.  
 
 
 
 
 
 
 
 
 
 
 
 76  
Patient 3 (Preoperative GH value: 66.3 ng/ml)
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Case 4: (Figure 16, 17, 18) 
This 17 year old male presented with acromegalic features. His random GH level was 99 
ng/ml. MRI showed a Hardy’s grade C pituitary adenoma with invasion into the right 
cavernous sinus. His vision was normal and he was not on replacements. He underwent 
radical excision of the pituitary adenoma on 15/6/2001. Post operative CT scan showed 
evidence of residual tumour near the right cavernous sinus. The GH level on the 1st post 
operative day was 26.1 ng/ml. He was lost to follow-up and came back only after 5 years 
when the MRI showed a large grade E tumour. He was on Tab. Prednisolone and Tab. 
Eltroxine. The GH level before the second surgery was 77 ng/ml. He underwent 
transsphenoidal resurgery on 13/12/2005 and the GH level on the seventh day following 
resurgery was 9.48 ng/ml. He was advised stereotactic radiation therapy, which he took in 
September 2006. He was also started on Tab. Cabergoline. His GH level during the time 
he was on SRT had risen again to 27.7 ng/ml. There were no more follow-ups available 
for this patient.   
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Fig 16(Case 4): MRI (T1 coronal with gadolinium) showing a grade C pituitary   
macroadenoma with cystic changes and invasion into the right cavernous sinus.  
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Fig 17(Case 4): Post operative MRI at 54 months (T1 coronal with gadolinium) showing 
right cavernous sinus residue. 
 
 
 
 
 
 80  
Figure 18
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Case 5: (Figures 19, 20) 
This 40 year old lady presented with acromegalic features for 6 years. Her random GH 
level was 33.7 ng/ml. MRI showed a 9 mm size microadenoma. Her vision was normal. 
She underwent radical excision of the pituitary adenoma. The GH level on the 1st post 
operative day was 0.85 ng/ml and on the 7th post operative day was 1.95 ng/ml. Two 
follow-ups later at 18 months she continued to be in remission with a GH level of 0.354 
ng/ml and IGF-1 of 65 ng/ml. She was a diabetic and hypertensive and she required the 
same dose of medication as preoperatively.  
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Fig 19(Case 5): MRI (T1 sagittal with gadolinium) showing a pituitary microadenoma. 
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Case 6 : (Figures 21,22) 
 
This 31 year old male presented with acromegalic features for 10 years. The preoperative 
GH level was 38.8 ng/ml. MRI showed a Hardy’s grade A pituitary macroadenoma. . He 
underwent radical excision of the pituitary adenoma. The 1st post operative day GH level 
was 0.8 ng/ml. He was in remission till 56 months after surgery when his GH level 
showed an increase to 1.09 ng/ml. However since the IGF-1 level was normal (70 ng/ml), 
he is under observation. He would require adjuvant therapy should the IGF-1 level rise.  
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Fig 21(Case 6): MRI (T1 coronal with gadolinium) showing a grade A pituitary 
macroadenoma. 
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DISCUSSION 
 
The treatment of acromegaly is aimed at reduction of GH levels so as to avoid the 
harmful systemic effects of raised serum GH level.  These include cardiovascular, 
metabolic and neoplastic changes. Transsphenoidal surgery (TSS) remains the first 
choice of treatment for acromegaly. It is effective and safe and is able to reverse 
metabolic and cardiovascular complications related to the disease. However, complete 
removal is not always possible and adjuvant therapy in the form of dopamine agonists, 
somatostatin analogs and radiotherapy are often required. Although recent studies show 
encouraging results with somatostatin analogues and GH receptor antagonists, these 
drugs are exorbitantly expensive and their use in developing countries is limited.  
 
In our study population, preoperative data such as age and sex distribution, tumor 
grading, duration of symptoms and preoperative GH concentration were comparable with 
other studies. Among the presenting complaints, visual deficits were present in a higher 
percentage of patients (35%) as compared to published literature. A large majority 
(91.6%) of the adenomas were macroadenomas and more than a third (37.5%) of the 
adenomas were invasive.  
 
Throughout the 1980s, post-operative GH levels < 5 ng/ml were considered as criteria of 
biochemical remission of disease, allowing a surgical success in more than 75% of 
patients in some large series. But epidemiologic studies have shown that mortality rates 
among treated acromegalic patients are higher than those of the normal population until 
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GH and IGF-I levels are normalized. This means an age and gender normalized IGF-1 
and post glucose suppressed GH levels of less than 1 ng/ml.  
 
The latest stringent criteria recommended by the Acromegaly treatment consensus 
workshop, were used in this study (normal IGF-1 level and post glucose suppressed GH 
levels of less than 1 ng/ml). The assay used in our institute was a highly sensitive 
chemiluminescent immunoassay with a sensitivity of 0.01 ng/ml.   
 
The earliest postoperative timing of assessment of cure was 3 months, which according to 
literature (102) is the earliest time for assessing both post-glucose suppression nadir GH 
level and IGF-1 level to determine outcome. 
 
A method that would identify those patients who have not responded to surgery in the 
early postoperative period itself would allow the early institution of adjuvant therapy to 
normalize the GH level quickly. 
 
 
 
 
.  
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PREDICTORS OF CURE 
 
The early postoperative GH values were evaluated with regard to sensitivity, specificity 
and their predictive values for the outcome of the operation. We found that the 1st and 7th 
postoperative day GH levels were highly predictive of the surgical outcome.  
 
Thus, a 1st postoperative day GH level of more than 2 ng/ml implied that at 3 months, the 
chance of a cure was only 3.6%. Similarly a 7th postoperative day GH level of more than 
2 ng/ml implied a chance of cure of only 11.6% at 3 months.  These findings support 
previous reports on the value of early postoperative GH measurements in determining 
surgical outcome in the treatment of acromegaly. Feelders et al (102) (GH level at 1 week 
of <0.5 ng/ml), Freda et al (108) (GH level of < 3 ng/ml in days 2-4 after surgery), 
Takahashi et al (101) (GH < 1ng/ml at 1 month postoperatively) and Valdemarsson et al 
(100) (Mean GH level at 1 week of <4.8 ng/ml), all these papers have shown a high 
specificity and predictive value of early postoperative GH levels. Thus, is our institution, 
patients with an early postoperative GH level of > 2 ng/ml at kept under close 
observation with serial follow-up evaluations. A persistent high GH level at follow-up or 
a rise in GH level with a concordant high IGF-1 level, is an indication for adjuvant 
therapy. However those patients who have a normal IGF-1 level with a raised GH value 
are not started on additional therapy unless, the IGF-1 level too rises and crosses the age 
and gender matched normal range.   
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We also evaluated other predictors of cure in our study namely the duration of symptoms, 
size of the tumour, preoperative growth hormone levels, Hardy’s grade, invasiveness of 
the tumour and immunohistochemistry findings. By univariate analysis, preoperative GH 
levels of less than 34 ng/ml were found to be the most statistically significant in 
predicting a cure, with an odd’s ratio of 6.45 and p-value of 0.002. Although the lower 
Hardy’s grade tumours (A, B, C) had an odd’s ratio of 6.61 as compared to Hardy’s grade 
D, E tumours, the p-value was not significant (0.45). Microadenomas also fared much 
better than macroadenomas with a surgical cure rate of 60% as against 26% for 
macroadenomas and 15% for invasive tumours.  These findings were similar to those 
already described in literature.  
 
The radicality of the excision was not found to be significant in predicting the outcome. 
This meant that the surgeon’s impression of radicality of excision was not a good 
indicator of the extent of excision. 
 
Cytokeratin immuostaining characteristic of the tumour was also not found to have 
statistically significant implication on cure. According to literature, sparsely granulated 
growth hormone secreting pituitary adenomas (cytokeratin positive) tend to be 
macroadenomas and more invasive and hence have lower surgical cure rates (27-29). 
However in our study group there was no difference in the cure rates between sparsely 
and densely granulated adenomas.   
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CURE RATES 
 
In spite of there being a consensus statement, there are still studies which used higher GH 
level definitions as cure. An example is the series published by Abbasioun et al (2006) 
(47) of 151 patients operated over a period of 23 years. They achieved a cure rate of 
94.2% using a cure criterion of 10 ng/ml. According to the author, in developing 
countries with limited resources and limited modalities of adjuvant therapy, clinical 
control and the patient “being happy” at follow-up, could be considered good outcomes. 
This could reflect reluctance on the part of authors to accept an extremely stringent 
criteria for cure, as the cure rates would then be abysmally low. 
We used stringent criteria for cure as defined by Guistina et al (Consensus statement, 
2000- post glucose suppression nadir GH value of < 1 ng/ml and a normal IGF1). 
In published literature, the cure rates with the stringent criteria of nadir GH levels < 1.0 
ng/ml during a GTT vary from 35.5% to 84.4% (48,51,53,56,57,58,60,61,62,64) 
In this series, when the post-glucose suppressed values of GH were considered alone as 
criteria of remission, in microadenomas the cure rate was 60% as compared to 26 % in 
macroadenomas. The remission rates fell to 0% in Hardy’s grade E tumours. The overall 
cure rates attained with multimodality treatment was 41%. A significant proportion of 
tumours in our study were invasive at surgery or on imaging (35.7%). In this subset, the 
overall remission rate was 35%, as compared to noninvasive macroadenomas, where the 
overall cure rate was 45%.  
But we found a significant rise in the overall cure rate to 71% when normalized IGF-1 
level was used alone as a criteria of cure.  IGF-1 levels were available in only 42 of the 
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56 patients with follow-up. According to Freda et al (69), as long as IGF-1 normalization 
is maintained, these patients can be observed without additional therapy.   Adjuvant 
therapy is necessary only when IGF-1 shows a rising trend. Swearingen et al (66) had a 
57% surgical cure rate using only normal IGF-1 as criterion for cure.  
 
 
Cure rates with the stringent criteria of nadir GH levels < 1.0 ng/ml during a GTT vary 
from 35.5% to 84.4% (Refer Table 2). The cure rate in this series is lower than what is 
described in literature. However a recently published study showed similar cure rates in 
the United Kingdom (46) that analyzed results from 22 centers (contributing more than 
10 cases in the study period) in the United Kingdom, which do transsphenoidal surgery 
for acromegaly in the duration form 1975-2004. They used a basal GH < 5ng/ml and/or 
normal IGF-1 levels, 1 year after surgery, as criteria for cure. There were 2 significant 
observations from the study. The first and surprising one was that cure rates for 
acromegaly in U.K. were significantly lower than those reported in literature. The overall 
cure rate was 39%, it was 56% for microadenomas and 26% for macroadenomas. 
Microdenoma cure rates ranged from 33-71% and macroadenoma cure rated ranged from 
8-56%, between the centers. When they compared cure rates from pre-1985 to that from 
2000-2004, another interesting trend was noted. Cure rates for microadenoma improved 
from 38% to 67% and for macroadenomas from 29% to 38%. This stressed on surgical 
experience and case load as having positive impact on cure rates. They explained the 
discrepancy between cure rates in their study and those published in literature, as being 
partly related to the fact that centers which had good results published while others do 
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not. This study by Bates et al (46) demonstrates the wide range of cure rates in a 
developed country, even with less stringent criteria than that recommended by Guistina et 
al (25). In our study, the overall cure rate was 28.5% using the criteria of post OGTT GH 
level of < 1 ng/ml, and would be higher if the criterion used by Bates et al (46) is applied. 
Another reason for the lower cure rates in this study could be the high proportion of 
invasive adenomas (35%). But other series have also found about 1/3rd of the adenomas 
to be invasive (62).  
 
Radiation therapy is an important adjunct in the management of acromegaly. In our study 
group, 13 (23%) underwent radiation therapy, of which 11 patients had stereotactic 
radiation therapy and 2 underwent conventional radiation therapy. Thus almost a quarter 
of the patients had adjuvant therapy in the form of radiation. Among these patients, 3 
went into remission following RT, the earliest being, 1 year after initiation of radiation 
therapy. The late effect on decreasing GH levels is a drawback of RT and it has been 
shown in literature (74), that conventional radiation therapy achieves GH levels of < 1 
ng/ml in only 9% of the patients at 2 years and in 77% of the patients at 15 years, when 
used as an adjunct to surgery. Further, the long term incidence of hypopituitarism can 
reach upto 90% following radiation therapy (74). Stererotactic radiation therapy achieves 
the same control of GH levels, with lower incidence of hypopituitarism (5%-29%) (77-
79). Therefore patients receiving RT need to be on close follow-up so that hormonal 
replacements can be started at the earliest evidence of hypopituitarism. 
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Based on our experience with GH secreting pituitary adenomas, we suggest an algorithm 
to manage these difficult tumors (Figure 23). Transsphenoidal surgery is the first line of 
management. In those tumors, where a radical excision has been achieved, further 
treatment will depend on the 7th postoperative day post glucose suppressed GH levels. As 
evidenced in our study, those with 7th postoperative day GH level of < 2 ng/ml have a 
high chance of cure and are hence kept on follow-up without any need for additional 
treatment. The group of patients who have undergone a radical excision but have a 7th 
day GH of > 2ng/ml, need to be given a trial of medical therapy with Tab. Cabergoline 
and the response evaluated after 3 months. Although the criteria of cure is < 1 ng/ml with 
a normalized IGF-1, literature has shown that those with a normal IGF-1 and GH < 5 
ng/ml, have long term mortality rates comparable to normal population and less than  5 
ng/ml has been used a criterion of cure (46). Thus, this group of patients can be kept 
under very close observation with annual check ups. However, in the patients were the 
IGF-1 level is high and the GH level has not dropped to < 1ng/ml, further management 
would depend on the MRI Brain findings. If the MRI shows accessible residue, then a 
second TSS can be planned followed by RT, else direct RT would be the treatment of 
choice at this juncture.  
 
The patients with partial/subtotal excision of tumors will most likely need RT. But there 
might be a small subset that might show a good response to Tab. Cabergoline, and these 
patients can be kept on follow-up.  
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Somatostatin analogs have not been discussed in the algorithm because of the exorbitant 
costs, which very few of our patients can afford. However, literature does show 
promising results with this group of drugs, both pre- and post-operatively. These drugs 
will have a significant role to play in a developing country like ours, once the costs are 
reduced.  
 
Thus, surgical outcomes for acromegaly remain less than satisfactory and early 
postoperative GH levels help us in predicting the surgical failures early. With the advent 
of modern microsurgical techniques including endoscopy-assisted microsurgery operative 
success for acromegaly may continue to improve. However, for the promising results of 
newer generation medical therapies in the form of somatostatin analogues and 
pegvisomant to be translated into reality, the costs need to be reduced so that they can 
help a larger population.  
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RECOMMENDATIONS: 
 
1. Primary care physicians play a major role in an early identification of acromegaly and 
resources should be directed toward increased awareness of the disease and its diagnosis 
in this provider group. This would lead to early identification of the disease and thus 
better outcomes.  
 
2. A high preoperative GH level of > 34 ng/ml and Hardy’s grade D,E tumours  indicate 
poor outcomes and the inevitable possibility of adjuvant therapy needs to be kept in 
mind.   
 
3. Early post operative GH levels should be done routinely as they have a good sensitivity 
and specificity to predict surgical failures. 
 
4. Those patients with a post operative GH > 5 ng/ml and surgically inaccessible tumour 
residue will probably require adjuvant radiation therapy.  
 
5. Patients with a high GH level (1-5 ng/ml) but a normal IGF-1 need not be started on 
additional therapy and can be kept on follow-up.  
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 Appendix-1 
 
PROFORMA FOR PATEINTS UNDERGOING TRASSPHENOIDAL SURGERY 
FOR ACROMEGALY 
 
Name: 
 
Age/Gender: 
 
Hospital Number: 
 
Date of surgery: 
 
Duration of acromegaly: 
 
Diabetes: yes/no Duration: 
 
Hypertension: yes/no Duration: 
 
Visual symptoms: Acuity/Fields 
 
MRI: Macroadenoma/Microadenoma 
 
Hardy’s grade: A/B/C/D/E 
 
Invasive: yes/no 
 
Hemorrhage/Cysts: yes/no 
 
Preoperative Hormonal profile: 
 
Prolactin/Cortisol/TFT/FSH/LH 
 
Basal Growth hormone level: 
 
Growth hormone level (post glucose suppression): 
 
Preoperative replacements: Steroids (yes/no), Eltroxin (yes/no) 
 
Early postoperative growth hormone levels: 
 
First postoperative day: 
 
Seventh postoperative day:  
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Surgery:  
 
Invasion: nil/left cavernous sinus/right cavernous sinus/sella and sphenoid/all 
 
Excision: partial/subtotal/radical 
 
Gland seen: yes/no 
 
Gland preserved: yes/no 
 
If subtotal resection, site of residue: 
 
Biopsy: 
 
Complications: Meningitis (yes/no), CSF rhinorrhoea (yes/no), hyponatremia(yes/no), 
hypocortisolism(yes/no). 
 
 
Radiation therapy: yes/no (SRT/conventional) 
 
Follow-up 
 
Acromegaly: 
 
Diabetes: 
 
Hypertension: 
 
GH levels: 
 
IGF-1 level: 
 
MRI: 
 
Advice: 
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Appendix- 2 
 
Histopathology methodology 
Light microscopy 
Routine histology: 
Tissues had been fixed in 10% buffered formalin, routinely processed and embedded in 
paraffin. 5 µm sections were stained with hematoxylin and eosin. 
Immunohistochemistry 
All tumors were immunostained for the full spectrum of pituitary hormones using the 
streptavidin-biotin peroxidase complex method. Table 2.1 provides specific information 
on each of the antibodies used, its dilution and the antigen retrieval method utilized.  
As the basic protocol for immunostaining is essentially similar for all antibodies, the 
protocol given below was followed for each of the antibodies.  
 
 
Basic protocol: 
Immunohistochemical staining was performed by the avidin-peroxidase technique using 
the appropriate antibody as detailed in Table. Representative 5µ sections of each case 
were mounted on poly-L-Lysine coated slides and incubated overnight at 37 0 C. Section 
of a positive control was used with each batch. Negative controls were achieved by 
omitting the primary antibody. Sections were deparaffinized followed by rehydration in 
decreasing ethanol concentrations and placed in distilled water. Appropriate antigen 
retrieval techniques were adopted depending on the antibody used. The antigen retrieval 
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technique adopted for each case is specified in the Table. Following antigen retrieval, the 
sections were covered with normal human pooled serum (1:5 dilution, Institutional Blood 
Bank) and incubated for 15 minutes. All excess liquid was drained off the slide by gentle 
tapping and the sections covered with the diluted antibody, and incubated overnight at 40 
C. The slides were then rinsed in Tris-buffered saline thrice for 5 minutes each. The 
sections were then drained and covered by diluted secondary antibody, biotinylated rabbit 
anti mouse (1:200 dilution, DAKO Patts, Denmark) and incubated for 30 minutes at room 
temperature. The slides were then rinsed in Tris-buffered saline thrice for 5 minutes each. 
Endogenous peroxidase was blocked with 0.5% hydrogen peroxidase (Qualigens) in 
methanol by incubating the slides covered with solution for 30 minutes. The sections 
were again rinsed in Tris-buffered saline thrice for 5 minutes each. The sections were 
then drained and covered with peroxidase conjugated avidin (1:200 dilution, DAKO 
Patts, Denmark) and incubated for 30 minutes. The slides were rinsed with 3 changes of 
Tris-buffered saline for 5 minutes each. The slides were then developed using freshly 
prepared diaminobenzidine tetrahydrochloride solution (DAKO Patts, Denmark) 
containing hydrogen peroxide, for 10 minutes. At this point positive controls were 
checked to ascertain the end of incubation. The sections were counterstained with Harris 
Hematoxylin for 10 seconds. The sections were then dehydrated, cleared, and mounted 
with DPX as mounting medium.  
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             Table Specifications of antibodies used for immunohistochemistry 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interpretation of cytoplasmic staining for pituitary hormones, GH, PRL,  
ACTH, TSH, FSH, LH and α-SU alpha subunit 
 
 
Tumors with cells displaying dark brown strong cytoplasmic stain were considered 
immunopositive for the corresponding antibody. 
Antibody Company Type Dilution Antigen Retrieval 
Growth Hormone DAKO 1:80 Monoclonal Heat 
Prolactin DAKO 1:400 Monoclonal Heat 
ACTH DAKO 1:150 Monoclonal No pre-treatment 
TSH BIOGENEX 1:100 Monoclonal Proteinase K 
FSH BIOGENEX 1:200 Monoclonal Trypsinisation 
LH BIOGENEX 1:25 Monoclonal Proteinase K 
Alpha subunit BIOGENEX 1:50 Monoclonal No pre-treatment 
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Age (Yr.)   Median Central 95% Range 0.1%ile 
21-25 203 116-358 84
26-30 196 117-329 87
31-35 188 115-307 87
36-40 176 109-284 83
41-45 164 101-267 76
46-50 154 94-252 70
51-55 144 87-238 65
56-60 135 81-225 60
61-65 126 75-212 55
66-70 118 69-200 51
71-75 110 64-188 47
102
40
76-80 59-177 43
81-85 95 55-166
                                                    Appendix-3 
                                    IGF-1 Adult reference ranges  
                                                 (IGF-1, ng/ml) 
